PAP
ACRS icon

Persistent Asset Partners’s Aclaris Therapeutics ACRS Stock Holding History

Persistent Asset Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,259
Closed -$67K – 326
2025
Q4 		$67K Buy
+22,259
New +$56.2K 0.03% 283

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Persistent Asset Partners's ACRS Position: Q1 2026 in Review

Persistent Asset Partners sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 22,259 shares — an estimated $67K sold.

Persistent Asset Partners first reported a position in ACRS in Q4 2025 and held it in 1 quarter. The position peaked at $67K in Q4 2025. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Persistent Asset Partners reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 22,259 Aclaris Therapeutics shares in Q1 2026, an estimated $67K.
  • Persistent Asset Partners first reported a position in Aclaris Therapeutics in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Aclaris Therapeutics position peaked at $67K in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.